- Investing.com
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers deliver medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Oncology Powerhouse | McKesson's strategic focus on oncology and biopharma services positions it for sustainable double-digit growth in high-value healthcare segments |
Acquisition Spree | Explore McKesson's bold moves in acquiring oncology assets, including a $2.49 billion stake in Florida Cancer Specialists, enhancing market position |
Financial Resilience | Learn how McKesson's strong US Pharma segment performance and raised guidance reflect its robust financial health and growth potential |
Data-Driven Future | Delve into McKesson's enhanced data capabilities from recent acquisitions, potentially unlocking new revenue streams and competitive advantages |
Metrics to compare | MCK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMCKPeersSector | |
---|---|---|---|---|
P/E Ratio | 27.6x | 19.9x | −0.4x | |
PEG Ratio | 1.86 | −0.02 | 0.00 | |
Price/Book | −43.9x | 9.0x | 2.6x | |
Price / LTM Sales | 0.3x | 2.4x | 3.1x | |
Upside (Analyst Target) | 5.7% | 7.5% | 51.1% | |
Fair Value Upside | Unlock | 6.4% | 8.9% | Unlock |